Intellia Therapeutics Stock Rises on FDA Priority Review for Gene-Editing Therapy

Shares of Intellia Therapeutics (NTLA) rose more than 4% in pre-market trading after the U.S. Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) for its gene-editing therapy, lonvoguran ziclumeran (lonvo-z). The agency granted the application a Priority Review, setting a Prescription Drug User Fee Act (PDUFA) target action date for March 10, 2027.

Key Regulatory Developments

The FDA's Priority Review designation is a significant milestone, as it shortens the standard review timeline for drugs that could offer major advances in treatment. In a further positive development for Intellia, the agency indicated that it does not currently plan to convene an advisory committee to discuss the application. This step removes a potential layer of regulatory uncertainty from the approval process.

If approved, lonvo-z could become the world's first *in vivo* CRISPR-based therapy, a treatment administered directly into the body to edit genes. The therapy is intended for patients with hereditary angioedema (HAE), a rare genetic disorder that causes severe swelling attacks.

Supporting Clinical Data

The BLA submission is supported by strong results from the Phase 3 HAELO trial, which enrolled 80 patients. According to data cited in the application, the trial demonstrated significant efficacy for lonvo-z:

Ad

• An 87% reduction in the average monthly number of HAE attacks compared to a placebo.
• 62% of patients treated with lonvo-z remained completely attack-free and did not require prophylactic therapy during the six-month evaluation period.

Market Reaction and Analyst Outlook

The positive regulatory news prompted a specific rally in Intellia's stock, which outperformed a largely negative broader market. The move appeared to be driven entirely by company-specific catalysts, as no material news was released by gene-editing peers such as Beam Therapeutics, Editas Medicine, or CRISPR Therapeutics.

Following the announcement, analysts at Citizens reiterated a Market Outperform rating on Intellia with a $30.00 price target. The firm's valuation model attributes approximately $24 per share of value to the HAE therapy alone, suggesting significant commercial potential if the drug gains approval and is launched in the U.S., which is targeted for the first half of 2027.